| Literature DB >> 35042900 |
Koukeo Phommasone1, Xaipasong Xaiyaphet2, Jose A Garcia-Rivera3, Robert D Hontz3, Viengmone Pathavongsa4, Patsalin Keomoukda2, Malavanh Vongsouvath2, Mayfong Mayxay2,5,6,7, Manivanh Vongsouvath2, Paul N Newton2,7, Elizabeth A Ashley2,7, Audrey Dubot-Pérès2,8.
Abstract
With the advent of highly sensitive real-time PCR, multiple pathogens have been identified from nasopharyngeal swabs of patients with acute respiratory infections (ARIs). However, the detection of microorganisms in the upper respiratory tract does not necessarily indicate disease causation. We conducted a matched case-control study, nested within a broader fever aetiology project, to facilitate determination of the aetiology of ARIs in hospitalised patients in Northeastern Laos. Consenting febrile patients of any age admitted to Xiengkhuang Provincial Hospital were included if they met the inclusion criteria for ARI presentation (at least one of the following: cough, rhinorrhoea, nasal congestion, sore throat, difficulty breathing, and/or abnormal chest auscultation). One healthy control for each patient, matched by sex, age, and village of residence, was recruited for the study. Nasopharyngeal swabs were collected from participants and tested for 33 pathogens by probe-based multiplex real-time RT-PCR (FastTrack Diagnostics Respiratory pathogen 33 kit). Attributable fraction of illness for a given microorganism was calculated by comparing results between patients and controls (= 100 * [OR - 1]/OR) (OR = odds ratio). Between 24th June 2019 and 24th June 2020, 205 consenting ARI patients and 205 matching controls were recruited. After excluding eight pairs due to age mismatch, 197 pairs were included in the analysis. Males were predominant with sex ratio 1.2:1 and children < 5 years old accounted for 59% of participants. At least one potential pathogen was detected in 173 (88%) patients and 175 (89%) controls. ARI in admitted patients were attributed to influenza B virus, influenza A virus, human metapneumovirus (HMPV), and respiratory syncytial virus (RSV) in 17.8%, 17.2%, 7.5%, and 6.5% of participants, respectively. SARS-CoV-2 was not detected in any cases or controls. Determining ARI aetiology in individual patients remains challenging. Among hospitalised patients with ARI symptoms presenting to a provincial hospital in Northeastern Laos, half were determined to be caused by one of several respiratory viruses, in particular influenza A virus, influenza B virus, HMPV, and RSV.Entities:
Mesh:
Year: 2022 PMID: 35042900 PMCID: PMC8766494 DOI: 10.1038/s41598-022-04816-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Distribution of microorganisms in patients and controls, detected by qRT-PCR in nasopharynx, odds ratio, AFE, and AF.
| Pathogen | Proportion in case, n (%) | Proportion in control, n (%) | OR (95% CI) | AFE, % | AF, % |
|---|---|---|---|---|---|
| Influenza viruses | 73 (37.1) | 3 (1.5) | 97.2 | 36.1 | |
| Influenza B | 37 (18.8) | 2 (1) | 94.6 | 17.8 | |
| Influenza A | 35 (17.7) | 1 (0.5) | 97.1 | 17.2 | |
| Influenza A (H1N1) | 9 (4.6) | 0 | NA | NA | NA |
| Influenza C | 1 (0.5) | 1 (0.5) | 1 (0.06–15.98) | NA | NA |
| Parainfluenza viruses | 5 (2.5) | 5 (2.5) | 1 (0.29–3.45) | NA | NA |
| PIV 3 | 4 (2) | 0 | NA | NA | NA |
| PIV 1 | 1 (0.5) | 1 (0.5) | 1 (0.06–15.98) | NA | NA |
| PIV 4 | 0 | 2 (1) | NA | NA | NA |
| PIV 2 | 0 | 2 (1) | NA | NA | NA |
| Human coronaviruses | 8 (4.1) | 5 (2.5) | 1.75 (0.51–5.97) | 42.9 | 6.3 |
| HCoV 229E | 4 (2) | 1 (0.5) | 4 (0.44–35.78) | 75.0 | 1.5 |
| HCoV OC43 | 4 (2) | 1 (0.5) | 4 (0.44–35.78) | 75.0 | 1.5 |
| HCoV NL63 | 0 | 3 (1.5) | NA | NA | NA |
| HCoV HKU1 | 0 | 0 | NA | NA | NA |
| HRV | 24 (12.2) | 55 (31.5) | NA | NA | |
| HMPV A&B | 18 (9.1) | 4 (2) | 82.1 | 7.5 | |
| RSV A&B | 16 (8.1) | 4 (2) | 80.0 | 6.5 | |
| ADV | 12 (6,1) | 24 (12.2) | NA | NA | |
| EV | 5 (2.5) | 8 (4.1) | 0.57 (0.17–1.95) | NA | NA |
| BocaV | 5 (2.5) | 8 (4.1) | 0.5 (0.12–1.99) | NA | NA |
| HPeV | 2 (1) | 0 | NA | NA | NA |
| 86 (43.6) | 123 (62.4) | NA | NA | ||
| 81 (41.1) | 120 (61) | NA | NA | ||
| 66 (33.5) | 94 (47.7) | NA | NA | ||
| 17 (8.6) | 34 (17.3) | NA | NA | ||
| 14 (7.1) | 47 (23.9) | NA | NA | ||
| 11 (5.6) | 6 (3) | 2 (0.68–5.85) | 50 | 2.8 | |
| 1 (0.5) | 0 | NA | NA | NA | |
| 1 (0.5) | 4 (2) | 0.25 (0.03–2.24) | NA | NA | |
| 0 | 3 (1.5) | NA | NA | NA | |
| 0 | 0 | NA | NA | NA | |
| 0 | 0 | NA | NA | NA | |
| 0 | 1 (0.5) | NA | NA | NA |
AFE, attributable fraction among the exposed = (1 − 1/OR) * 100; AF, attributable fraction = AFE * Proportion of a given organism in case/100; OR, odds ratio; CI, confident interval; NA, not applicable; HRV, human rhinovirus; HMPV, human metapneumovirus; RSV, respiratory syncytial virus; ADV, adenovirus; EV, enterovirus; BocaV, human bocavirus; HPeV, human parechovirus.
Statistically significant OR are written in bold.
Participant characteristics and their clinical signs and symptoms.
| Variable | Case, n = 197 | Control, n = 197 |
|---|---|---|
| Male:Female | 108:89 | 108:89 |
| Age (year), median (IQR) | 4 (0.41–65) | 4.1 (0.41–67) |
| Age group, n (%) | ||
| ≤ 2 years old | 58 (29.4) | 51 (25.9) |
| > 2 to ≤ 5 years old | 58 (29.4) | 65 (32.9) |
| > 5 to ≤ 15 years old | 59 (29.9) | 59 (29.9) |
| > 15 years old | 22 (11.2) | 22 (11.2) |
| Number of days of fever, median (IQR) | 3 (2–5) | 0 |
| History of fever over the last 72 h, n (%) | 197 (100) | 0 |
| Tympanic temperature (ºC), median (IQR) | 38.0 (37.2–38.3) | 36.9 (36.7–37) |
| Rigors, n (%) | 20 (10.2) | 0 |
| Headache, n (%) | 57 (28.9) | 0 |
| Arthralgia, n (%) | 3 (1.5) | 1 (0.5) |
| Myalgia, n (%) | 28 (14.2) | 2 (1) |
| Back pain, n (%) | 3 (1.5) | 1 (0.5) |
| Nausea, n (%) | 34 (17.3) | 0 |
| Vomiting, n (%) | 68 (33.1) | 0 |
| Dysuria, n (%) | 3 (1.5) | 0 |
| Diarrhea, n (%) | 22 (11.2) | 0 |
| Abdominal pain, n (%) | 9 (4.6) | 0 |
| Shortness of breath, n (%) | 19 (9.6) | 0 |
| Difficulty breathing, n (%) | 30 (15.2) | 0 |
| Cough, n (%) | 167 (84.8) | 0 |
| Sputum, n (%) | 105 (53.3) | 0 |
| Sore throat, n (%) | 24 (12.2) | 0 |
| Runny nose, n (%) | 106 (53.8) | 4 (2) |
| Seizure, n (%) | 6 (3) | 0 |
| Respiratory rate/min, median (IQR) | 29 (20–30) | 26 (25–30) |
| Fast breathing€ (for children ≤ 5 years old), n (%) | 10/116 (8.6) | 0 |
| Abnormal chest auscultation, n (%) | 42 (21.3) | 0 |
| Pharyngeal erythema, n (%) | 143 (72.6) | 0 |
| Pneumonia$ (for children ≤ 5 years old), n (%) | 10 (8.6%) | 0 |
| Severe pneumonia (for children ≤ 5 years old), n (%) | 6 (5.2%) | 0 |
| Duration of hospitalization (days), median (IQR) | 3 (3–5) | 0 |
| Death, n (%) | 0 | 0 |
| Any PCV vaccination, n (%) | 49/100 (49.0) | 45/119 (37.8) |
| 1 dose, n | 3 | 4 |
| 2 doses, n | 1 | 1 |
| 3 doses, n | 44 | 29 |
€Fast breathing = aged 2–11 months: ≥ 50 breaths/min, aged 1–5 years: ≥ 40 breaths/min.
$Pneumonia and severe pneumonia were defined according to WHO criteria[19]. Children who presented with cough or difficulty breathing and had fast breathing or chest indrawing, were classified as having pneumonia. Children who presented with cough or difficulty breathing and had at least one of the following criteria were classified as severe pneumonia: oxygen saturation < 90%, while breathing room air, or central cyanosis; severe respiratory distress; signs of pneumonia with a general danger sign (inability to breastfeed or drink, lethargy or reduced level of consciousness, convulsions, vomiting).
*The number of doses were recorded if the vaccination card was seen by the study team. The pneumococcal conjugate vaccine 13 (PCV) was included in the Expanded Program on Immunization in Laos about 5 years before this study was conducted.
Figure 1Single and multiple organism detection in ARI cases. PIV, parainfluenza virus; HCoV, human coronavirus; HRV, human rhinovirus; HMPV, human metapneumovirus; RSV, respiratory syncytial virus; ADV, human adenovirus; EV, enterovirus; BocaV, human bocavirus; HPeV, human parechovirus; PCP, Pneumocystis jirovecii.
Figure 2Prevalence of viral pathogens detected among cases and controls. Influenza viruses: influenza A virus, influenza B virus and influenza C virus. HMPV, human metapneumovirus; RSV, respiratory syncytial virus; ADV, adenovirus; HRV, human rhinovirus; BocaV, human bocavirus; HCoV, human coronavirus including HCoV 229E and HCoV OC43, and HCoV NL63; PIV 1–4, parainfluenza virus 1, 2, 3 and 4; EV, enterovirus; HPeV, human parechovirus.
Figure 3Temporal distribution of detection of influenza A virus, influenza B virus, human metapneumovirus, and respiratory syncytial virus in included ARI patients in relation to monthly average rainfall. Xiengkhuang rainfall data from Department of Meteorology and Hydrology, Lao PDR.
Figure 4Age distribution in all ARI patients and in patients positive for influenza viruses, respiratory syncytial virus (RSV) and human metapneumovirus (HMPV).
Environmental factors associated with ARI.
| Environment | Case, n (%) | Control, n (%) | Univariate analysis | |
|---|---|---|---|---|
| Crude OR (95% CI) | ||||
| Lao Loum ethnicity | 125 (63.5) | 109 (55.3) | ||
| Having children < 5 years in the house | 142 (72.1) | 148 (75.1) | 0.78 (0.44–1.37) | 0.397 |
| Crowdinga | 34 (17.3) | 34 (17.3) | 1 (0.58–1.70) | 1 |
| Smoker in the house | 56 (28.6) | 63 (32.1) | 0.84 (0.53–1.34) | 0.48 |
| Self-sufficientb | 191 (96.9) | 193 (97.9) | 0.5 (0.09–2.72) | 0.423 |
| Attended universityc | 103 (52.3) | 88 (44.7) | 1.48 (0.94–2.33) | 0.089 |
| Biomass fuels used | 187 (94.9) | 177 (89.8) | 2.25 (0.97–5.17) | 0.05 |
| Indoor pollutione | 90 (45.7) | 87 (44.1) | 1.07 (0.69–1.65) | 0.74 |
| Untreated drinking water | 4 (2) | 2 (1) | 3 (0.31–28.8) | 0.34 |
| No toilet/latrine | 1 (0.5) | 0 | NA | 1 |
Significant values are in bold.
aMore than 7 people living in the same house.
bThe income of the family is sufficient to live on judged by family.
cHighest form of education in the family.
dCharcoal or wood were used in cooking.
eMaking fire inside the house.
Organisms detected in nasopharynx in children who met the WHO pneumonia definition[19].
| Patient # | Severe | Flu | HCoV | HRV | HMPV | BocaV | RSV | HPeV | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 |
| 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 4 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 5* | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 |
| 6 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 |
| 7 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 0 |
| 8* | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| 9 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| 10 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 |
*Patients have received three doses of PCV-13.
Flu, influenza viruses; HCoV, human coronaviruses; HRV, human rhinovirus; HMPV, human metapneumovirus; BocaV, human bocavirus; RSV, respiratory syncytial virus; HPeV, human parechovirus; S. pneu, Streptococcus pneumoniae; K. pneu, Klebsiella pneumoniae; M. catarrhalis, Moraxella catarrhalis; B. pertussis, Bordetella pertussis; H. inf, Haemophilus influenzae.